Signal transduction

Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero

Retrieved on: 
Wednesday, April 12, 2023
SAB, San Francisco Bay Area, Special Program of Assisted Reproduction, AACR, SPORE, Science and technology in Asia, Vall, ESMO, American Society of Clinical Oncology, Cancer, American Association for Cancer Research, United States Air Force Scientific Advisory Board, Research, Oncology, Signal transduction, European Society for Medical Oncology, Cantley, Ioan Totu, AGIO, Harvard Medical School, ASCO, PI3K, United Nations Scientific Committee on the Effects of Atomic Radiation, Cell biology, Patient, UCSF, Drug discovery, Society, Agios Pharmaceuticals, IDeA Networks of Biomedical Research Excellence, Breast cancer, Disease, Pharmaceutical industry, Antibiotics, Medical device

To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.

Key Points: 
  • To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.
  • They include:
    Dr. Lewis Cantley : Dr. Cantley's work has helped define the field of signal transduction, and he notably discovered the PI3K pathway and its role in cancer.
  • "I am excited to join the Scientific Advisory Board of Totus Medicines.
  • The SAB advances Totus' efforts to continue to deliver unparalleled efficiency and accuracy with its groundbreaking drug discovery platform.

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Retrieved on: 
Thursday, February 16, 2023
Trial of the century, Lead, HPV, Cue, Cell signaling, Head, Selective, Nature, Patient, Signal transduction, University, Research, Modes of toxic action, Concept, Poster, Kennedy Institute, Kennedy Institute of Ethics Journal, Vaccine

The research is part of a strategic research collaboration that Cue Biopharma initiated with Dr. Michael Dustin’s laboratory at the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of the company’s interleukin 2 (IL-2) based CUE-100 series of biologics.

Key Points: 
  • The research is part of a strategic research collaboration that Cue Biopharma initiated with Dr. Michael Dustin’s laboratory at the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of the company’s interleukin 2 (IL-2) based CUE-100 series of biologics.
  • “The data continue to support the differentiated mechanism of action of Cue Biopharma’s Immuno-STAT CUE-100 series of biologics, by uniquely mimicking the natural process of immune synapse formation,” said Jesusa Capera-Aragones, Ph.D., post-doctoral researcher, Dustin laboratory of the Kennedy Institute at the University of Oxford.
  • “By simultaneously presenting a targeted antigen and the immunostimulatory molecule IL-2, Cue Biopharma’s biologics enable the specific and simultaneous engagement of IL-2 and T cell receptors, as it would occur in nature.
  • Dr. Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, added “We are very pleased with the research and collaboration with Dr. Dustin’s laboratory of the Kennedy Institute at the University of Oxford.

Insilico Medicine Nominates Potential First-in-Class Preclinical Candidate with Novel AI-Designed Structure for Novel AI-Discovered Target in Immuno-oncology

Retrieved on: 
Tuesday, December 20, 2022
Cancer, DGK, Fibrosis, PD-1, Signal transduction, DGKA, Inflammation, ADME, RNA-Seq, Research, AI, Insilico Medicine, Therapy, IND, DAG, Pharma, Doctor of Philosophy, RNA, Intelligence, Medical device, Pharmaceutical industry, In silico

It is another program fully discovered and designed by AI that Insilico has delivered from target identification to preclinical candidate nomination by leveraging its proprietary end-to-end AI platform, Pharma.AI.

Key Points: 
  • It is another program fully discovered and designed by AI that Insilico has delivered from target identification to preclinical candidate nomination by leveraging its proprietary end-to-end AI platform, Pharma.AI.
  • Immune checkpoint blockade has proven effective in a variety of malignancies, but the response rate of existing therapeutics remains low.
  • The diacylglycerol kinase family (DGKs) is an important player in signal transduction, phosphorylating the membrane lipid, diacylglycerol (DAG), to phosphatidic acid (PA).
  • The preclinical candidate ISM4312A is a potential first-in-class DGKA inhibitor with excellent potency and high selectivity in cancer immunotherapy.

IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board

Retrieved on: 
Wednesday, December 7, 2022
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Tao, Vall, Helen, Immune-mediated inflammatory diseases, Federalisation of the European Union, Ephraim, COVID-19, University of Barcelona, Natural killer T cell, Teaching hospital, Phosphorylation, Virus, Bristol Myers Squibb, Partnership, American Cancer Society, Inflammation, University, Hospital, University School, Machine learning, National academy, EFIS, MD, Signal transduction, Howard Hughes Medical Institute, Science, DNS, University of California, San Francisco, Faculty, Immunology, Homeostasis, Immune system, Microbiota, International Union of Immunological Societies, Patient, Immunotherapy, Research, Journal, Tyrosine, UCSF, IMID, Biomedical sciences, Long, DN Capital, Nicholas J. Pritzker, Pharmaceutical industry, Medical device, Biotechnology, Microbiology, Rheumatology

Members of the IMIDomics Immunology Advisory Board include:

Key Points: 
  • Members of the IMIDomics Immunology Advisory Board include:
    Andr Veillette, M.D.
  • Dr. Veillete is a member of the COVID-19 Vaccine Task Force and the Long COVID Task Force of the Government of Canada.
  • He serves on multiple academic and industry advisory boards and the Pfizer Board of Directors.
  • His research group studies Natural Killer cells, which recognize and eliminate cells that have become transformed or infected by viruses.

Disarming the immune system's lethal lung response

Retrieved on: 
Friday, September 23, 2022
Neuroscience, Inflammation, COVID-19, Ageing, Biomedical Research, Sepsis, Neutrophil, Nobel Prize, Neurodegeneration, Mouse, Environment, Infection, Signal transduction, Cancer, Cold, Blood, Protein, Weapon, Student, Hyperkinesia, Cold Spring Harbor Laboratory, Cell, Laboratory, SPRING, Tissue, Transfusion-related acute lung injury, Research, CSHL, Multimedia, Proning, Education, Disease, Death, PTP, Pharmaceutical industry, Vaccine, PTP1B

Lung tissue is saturated with blood vessels, making them very susceptible to neutrophil attacks.

Key Points: 
  • Lung tissue is saturated with blood vessels, making them very susceptible to neutrophil attacks.
  • If severe enough, acute lung injuries can lead to acute respiratory distress syndrome (ARDS), the leading cause of death due to COVID-19.
  • Nicholas Tonks , Caryl Boies professor of cancer research at Cold Spring Harbor Laboratory (CSHL), and his team have found a drug candidate that can prevent lethal lung inflammation in mice by inhibiting a protein called PTP1B.
  • "When you think about COVID-19, acute lung injury and ARDS underlie the fatal aspects of the disease," Tonks says.

Global ANCA Vasculitis Drug Pipeline Market Research Report 2022 Featuring GSK, AstraZeneca, Staidson Biopharmaceuticals, Bristol-Myers Squibb, InflaRx, Chia Tai Tianqing Pharmaceutical & Visterra - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, AstraZeneca, Eosinophilic granulomatosis with polyangiitis, NDA, II, Technology, Benralizumab, Asthma, Survival, Awareness, Macrophage, Disease, Signal transduction, Basophil, Vasculitis, MedImmune, GlaxoSmithKline, ANCA, FDA, Therapy, Eosinophil, News, III, Clinical trial, Immunoglobulin G, Microscopic polyangiitis, Acquisition, Discovery, Patient, Pharmaceutical industry

The "Global ANCA Vasculitis - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global ANCA Vasculitis - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "ANCA Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in ANCA Vasculitis pipeline landscape.
  • A detailed picture of the ANCA Vasculitis pipeline landscape is provided which includes the disease overview and ANCA Vasculitis treatment guidelines.
  • The assessment part of the report embraces, in depth ANCA Vasculitis commercial assessment and clinical assessment of the pipeline products under development.

InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

Retrieved on: 
Tuesday, August 2, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Conditional sentence, IBD, Autoimmune disease, Inflammation, Psoriasis, CEO, IFN, Cardiovascular disease, Inflammatory bowel disease, Signal transduction, Cancer, Quality of life, Clinical trial, Patient, Lupus, Degenerative disease, TYK2, Autoimmunity, HKEX, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Companys TYK2 JH2 allosteric inhibitor ICP-488 in China.

Key Points: 
  • InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Companys TYK2 JH2 allosteric inhibitor ICP-488 in China.
  • ICP-488 is a potent and selective TYK2 (tyrosine kinase 2) allosteric inhibitor being developed for the treatment of autoimmune diseases such as psoriasis and inflammatory bowel disease (IBD).
  • Dr. Jasmine Cui, the co-founder, Chairwoman and CEO of InnoCare said, ICP-488 is our third drug candidate entering into the clinic in the field of autoimmune disease.
  • We strategically focus on liquid cancer, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide.

US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL

Retrieved on: 
Sunday, July 24, 2022
Signal transduction, Death, Environment, United Kingdom, Injection, Virbac, Journal of Veterinary Internal Medicine, Human, Sarcoma, PKC, Extremities, Safety, Targeted alpha-particle therapy, Cancer, Recurrence, Tigilanol tiglate, DOI, Patient, Neoplasm, Pharmacokinetics, Animal, EBioMedicine, Wound healing, Pharmaceutical industry, Medical imaging, Vaccine

Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.

Key Points: 
  • Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.
  • QBiotics' lead oncology product, tigilanol tiglate, is a small molecule targeting a range of solid tumours across multiple species.
  • Tigilanol tiglate has a multimodal action that involves injected tumour responses as well as systemic responses in non-injected tumours.
  • Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate.

US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL

Retrieved on: 
Sunday, July 24, 2022
Signal transduction, Death, Environment, United Kingdom, Injection, Virbac, Journal of Veterinary Internal Medicine, Human, Sarcoma, PKC, Extremities, Safety, Targeted alpha-particle therapy, Cancer, Recurrence, Tigilanol tiglate, DOI, Patient, Neoplasm, Pharmacokinetics, Animal, EBioMedicine, Wound healing, Pharmaceutical industry, Medical imaging, Vaccine

Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.

Key Points: 
  • Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.
  • QBiotics' lead oncology product, tigilanol tiglate, is a small molecule targeting a range of solid tumours across multiple species.
  • Tigilanol tiglate has a multimodal action that involves injected tumour responses as well as systemic responses in non-injected tumours.
  • Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate.

NEW EARLY BREAST CANCER DRUG TO REDUCE RISK OF RECURRENCE OR DEATH NOW AVAILABLE IN THE PHILIPPINES

Retrieved on: 
Friday, July 8, 2022
Degenerative disease, FDA, Death, Patient, HER1, ALT, Spasm, Abdominal pain, Adult, Research, Nominal interest rate, DCIS, Breast cancer, Ductal carcinoma, HIV disease progression rates, IDF field hospital for Gazans, EC, Ophthalmology, European Commission, Abdominal distension, CI, Vomiting, Rash, Stomatitis, Diarrhea, Neurology, Woman, OS, Risk, Food, Nosebleed, HER2, AST, Signal transduction, Royal commission, Fatigue, Appetite, Incidence, NEW, Trastuzumab, Criticism of the Food and Drug Administration, Indigestion, Recurrence, Nausea, Medical imaging, Dietary supplement, Vaccine, Pharmaceutical industry, Dentistry

Their five-year risk of recurrence is reduced by 42% after completing 12 months of NERLYNX therapy.1

Key Points: 
  • Their five-year risk of recurrence is reduced by 42% after completing 12 months of NERLYNX therapy.1
    Chair of the Philippines' Cardinal Santos Medical Center, Dr Ma.
  • Luisa Abesamis-Tiambeng, said the NERLYNX approval was "a great step forward" for women in the Philippines who have been diagnosed with early breast cancer that is both HER2+ and HR+.
  • Dr Tiambeng commented: "We know that one in four women with this type of breast cancer are still at risk of recurrence, despite treatment with chemotherapy and trastuzumab-based therapy following their initial breast surgery.
  • HER2+ breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death.